This is true for pancreatic cancer, for which the overexpression of dopamine receptors, particularly DRD2 [10], was found, although some findings suggest a greater role for DRD1 receptors, as it was established that DRD1 activation may enhance antitumor activities in pancreatic cancer [12]. This evidence concerns the gene DRD2 and pancreatic neoplasm.